{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:37:47Z","timestamp":1792805867933,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023360","name":"St Vincent's Hospital Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023360","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults, with high risk of progression to end-stage kidney disease when untreated. Rituximab is commonly used in its treatment however many patients do not respond. Obinutuzumab is a novel anti-CD20 monoclonal antibody for which there is increasing observational evidence in treatment-resistant membranous nephropathy. The majority of evidence for its use relates to anti-phospholipase A2 receptor-(PLA2R) associated membranous nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-centre case-series of all patients at a tertiary nephrology centre in Melbourne, Australia, treated with Obinutuzumab for membranous nephropathy, between January 2023 and June 2024. All patients who received Obinutuzumab were included in this case-series, irrespective of PLA2R status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 5 patients with treatment-resistant membranous nephropathy, 3 had PLA2R-associated membranous nephropathy which had previously been refractory to, or relapsed on Rituximab therapy. All 3 patients with PLA2R-positive membranous nephropathy achieved complete immunological and clinical remission after receiving Obinutuzumab. The case of secondary PLA2R-negative membranous nephropathy only achieved partial remission after Obinutuzumab before unexpectedly dying from another cause. The case of recurrent PLA2R-associated membranous nephropathy in a renal allograft did not respond to Obinutuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case-series supports the existing evidence in favour of Obinutuzumab for treatment-resistant PLA2R-associated membranous nephropathy. To our knowledge it is the first reported use of Obinutuzumab in sarcoidosis-associated membranous nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-025-02224-6","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:43:50Z","timestamp":1740055430000},"page":"1809-1818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-1411","authenticated-orcid":false,"given":"Krita","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basu","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"1119","key":"2224_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/postgradmedj-2018-135729","volume":"95","author":"KC Keri","year":"2019","unstructured":"Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T (2019) Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J 95(1119):23\u201331. https:\/\/doi.org\/10.1136\/postgradmedj-2018-135729","journal-title":"Postgrad Med J"},{"issue":"2","key":"2224_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","volume":"329","author":"A Schieppati","year":"1993","unstructured":"Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G (1993) Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329(2):85\u201389. https:\/\/doi.org\/10.1056\/NEJM199307083290203","journal-title":"N Engl J Med"},{"issue":"1","key":"2224_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, MENTOR Investigators et al (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427","journal-title":"N Engl J Med"},{"issue":"4","key":"2224_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fern\u00e1ndez-Ju\u00e1rez","year":"2021","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, van de Logt A et al (2021) The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int 99(4):986\u2013998. https:\/\/doi.org\/10.1016\/j.kint.2020.10.014","journal-title":"Kidney Int"},{"issue":"4","key":"2224_CR5","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D et al (2021) Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol 32(4):972\u2013982. https:\/\/doi.org\/10.1681\/ASN.2020071091","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2224_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, GEMRITUX Study Group et al (2017) Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 28(1):348\u2013358. https:\/\/doi.org\/10.1681\/ASN.2016040449","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2224_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","volume":"56","author":"V Reddy","year":"2017","unstructured":"Reddy V, Klein C, Isenberg DA et al (2017) Obinutuzumab induces superior B-cell cytotoxicity to Rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford) 56(7):1227\u20131237. https:\/\/doi.org\/10.1093\/rheumatology\/kex067","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2224_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD et al (2022) B-cell depletion with Obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81(1):100\u2013107. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"2224_CR9","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22):4393\u20134402. https:\/\/doi.org\/10.1182\/blood-2009-06-225979","journal-title":"Blood"},{"issue":"9","key":"2224_CR10","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","volume":"5","author":"S Sethi","year":"2020","unstructured":"Sethi S, Kumar S, Lim K, Jordan SC (2020) Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep 5(9):1515\u20131518. https:\/\/doi.org\/10.1016\/j.ekir.2020.06.030","journal-title":"Kidney Int Rep"},{"issue":"6","key":"2224_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","volume":"76","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Fervenza FC, Zand L (2020) Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with Obinutuzumab: a report of 3 cases. Am J Kidney Dis 76(6):883\u2013888. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.444","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2224_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","volume":"23","author":"R Hudson","year":"2022","unstructured":"Hudson R, Rawlings C, Mon SY, Jefferis J, John GT (2022) Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to Obinutuzumab: a report of two cases. BMC Nephrol 23(1):134. https:\/\/doi.org\/10.1186\/s12882-022-02761-3","journal-title":"BMC Nephrol"},{"issue":"8","key":"2224_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100853","volume":"6","author":"Y Lin","year":"2024","unstructured":"Lin Y, Han Q, Chen L et al (2024) Obinutuzumab in refractory membranous nephropathy: a case series. Kidney Med 6(8):100853. https:\/\/doi.org\/10.1016\/j.xkme.2024.100853","journal-title":"Kidney Med"},{"key":"2224_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14331","author":"J Hao","year":"2024","unstructured":"Hao J, Wang J, Zhou P, Xu R, Chen X (2024) Obinutuzumab in untreated primary membranous nephropathy: AN observational case series. Nephrology (Carlton). https:\/\/doi.org\/10.1111\/nep.14331","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"2224_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ckj\/sfab250","volume":"15","author":"NE Ginth\u00f6r","year":"2021","unstructured":"Ginth\u00f6r NE, Artinger K, Pollheimer MJ, Stradner MH, Eller K (2021) Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with Obinutuzumab. Clin Kidney J 15(3):564\u2013566. https:\/\/doi.org\/10.1093\/ckj\/sfab250","journal-title":"Clin Kidney J"},{"issue":"11","key":"2224_CR16","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1111\/ajt.15514","volume":"19","author":"RR Redfield","year":"2019","unstructured":"Redfield RR, Jordan SC, Busque S et al (2019) Safety, pharmacokinetics, and pharmacodynamic activity of Obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant 19(11):3035\u20133045. https:\/\/doi.org\/10.1111\/ajt.15514","journal-title":"Am J Transplant"},{"key":"2224_CR17","doi-asserted-by":"publisher","first-page":"611317","DOI":"10.3389\/fmed.2020.611317","volume":"7","author":"G Moroni","year":"2020","unstructured":"Moroni G, Ponticelli C (2020) Secondary membranous nephropathy. A narrative review. Front Med (Lausanne) 7:611317. https:\/\/doi.org\/10.3389\/fmed.2020.611317","journal-title":"Front Med (Lausanne)"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02224-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02224-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02224-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:19Z","timestamp":1777564759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/7\/1809\/8457463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2224"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02224-6","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an observational case series and as such, ethical approval was not sought, as ethics approval is not generally required for case series at this institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Freely-given informed consent was obtained from all patients for inclusion in this case series and for submission to the journal. All information was deidentified as best as possible.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}